US Recall News

United States Recall News Alerts for Recalled Drugs, Food, Products, & Vehicles

MENUMENU
  • Home
  • About
    • Advertise
  • Full Recall News Archive
    • Top Story

      J&J Settles Talc Mesothelioma Settlement

      By Sandra Dalton, Staff Writer On January 6, 2020, Superior Court Judge Stephen Kaus announced that Johnson & Johnsons (J&J) had agreed to … [Read More...]

      Second Nature Brands Issues Allergy Alert on Undeclared Wheat in Gluten Free Reese’s Pieces Brownie Brittle

      Summary Company Announcement Date: March 23, 2023 FDA Publish Date: … [Read More...]

    • More Safety Articles
    • Federal Preemption of State Product Liability Law
  • Drug Recalls
    • Abilify
    • Benicar
    • Fluoroquinolones
    • Invokana
    • Lipitor
    • Nuplazid
    • Opioids
    • OxyContin
    • Pradaxa
    • Proton Pump Inhibitors (PPIs)
    • Risperdal
    • SSRI
    • Symptoms & Side Effects
    • Taxotere
    • Testosterone
    • Uloric
    • Valsartan
    • Xarelto
    • Zofran
  • Medical Devices
    • 3M Earplug
    • 3T Heater-Cooler System
    • Bair Hugger
    • Bipolar Hip System
    • Essure
    • Hip Replacements
    • Implanon
    • IVC Filters
    • Hernia Mesh
    • Power Morcellators
    • Shoulder Implants
    • Transvaginal Mesh
  • Food Recalls
    • FDA Press Releases
    • USDA Press Releases
  • Auto Recalls
    • Air Bags
    • Ignitions
    • NHTSA Press Releases
    • Off-Road Utility Vehicles
    • Snowmobiles
    • Tires
  • Other Products
    • Asbestos
    • Baby Products
    • Pet Products
    • Roundup
    • Talcum Powder
    • Toy Recalls
You are here: Home / Featured / The Mounting Case against Xarelto from FDA Direct Adverse Drug Reports

The Mounting Case against Xarelto from FDA Direct Adverse Drug Reports

October 12, 2015 By US Recall News Leave a Comment

In just the last four years, the FDA has raised many separate clarifications with Johnson & Johnson about the blood thinning drug Xarelto. These have included extra black box warnings about the possible contraindications, additional advertising requirements and further possible side effects that were not included on the original FDA approval in November 2011.

Despite the claim that it is simpler to prescribe and monitor then same-category anti-coagulant leader Warfarin, the case against using Xarelto and possible legal implications are mounting.

A January 2014 FDA notice highlighted that there isn’t an antidote to counteract excessive bleeding from the drug, and that this needed to be pointed out on the label.

This is significant from a number of angles. The first is that this is a big differentiator from Warfarin, which can be counteracted with certain plasma products and vitamin k.

In contrast, if a patient is administered Xarelto and experiences uncontrollable bleeding as a side effect, since there is no antidote, the patient’s death is a likely result.

A study published in the September 23, 2015 issue of Quarterwatch evaluated medical data from 2014 and highlighted that Xarelto accounted for more direct safety reports to the FDA, mostly from health professionals, than any other drug.

Direct reports to the FDA only account for 4.1% of the total of adverse drug effect reports received by the FDA in 2014, with the remainder coming directly from the manufacturers. The statistics indicate that problems need to be significantly greater before a medical professional will directly report to the FDA about adverse drug effects.  As Xarelto has had more direct reports to the FDA, 525 for 2014, than any other drug, there is a general feeling that the likelihood of a significant percentage of these developing into legal cases is perhaps greater than for other medications, because they are independent of manufacturer spin and marketing and generally of a higher quality.

The anti-coagulant market that Xarelto is trying to compete in is a huge one, and has long been dominated by Warfarin, which was first approved for use back in 1956.  It is also commonly used in hip and knee replacement surgery and for heart problems, which are some of the most common medical conditions and hence routinely diagnosed for millions of patients.

Quarterwatch reported that in 2014 there were 80,266,745 prescriptions for Warfarin and 1,758,016 for Xarelto. This marks the considerable lead that Warfarin has in the sector in terms of raw prescription numbers. However, considering that Xarelto costs 15 times as much ($3,000 a year compared to $200 for Warfarin) and has only been available since 2011, it is indicative of the giant steps this drug has taken in the blood thinning market.

It also has more prescriptions then the next two main ‘new coagulant class’ rivals combined (Dabigatran and Apixaban), and so making sure that its safety profile is acceptable becomes of much greater significance.

Taken together these factors are indicative of the potential for a much wider scale of problems with Xarelto, with the number of FDA direct reports showing the tip of a litigation iceberg destined to  emerge in the future.

Share this:

  • Facebook
  • Twitter
  • LinkedIn
  • Email
  • Print

Related

Filed Under: Featured, Xarelto Tagged With: Xarelto

About US Recall News

US Recall News provides recall news and information to the United States general public. Find all of the latest drug, food, products, and vehicle recall news as reported by U.S. government agencies and more.

Leave a Reply Cancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Facebook
Thomas Roney LLC
Economic Consulting

J&J Settles Talc Mesothelioma Settlement

January 15, 2020 By Advice Media

Second Nature Brands Issues Allergy Alert on Undeclared Wheat in Gluten Free Reese’s Pieces Brownie Brittle

March 23, 2023 By The FDA

Kawasaki Motors USA Recalls Engines Sold on Ferris and SCAG Riding Lawn Mowers Due to Burn and Fire Hazards

March 22, 2023 By The CPSC

Burnham Commercial Recalls Natural Gas Boilers Due to Burn Hazard (Recall Alert)

March 22, 2023 By The CPSC

Free Case Review

  • * = Required
    Privacy Policy
  • This field is for validation purposes and should be left unchanged.

Hero Highlight

J&J Settles Talc Mesothelioma Settlement

January 15, 2020 By Advice Media

Perfection Bakeries, d/b/a/ Aunt Millie’s Issues Allergy Alert on Undeclared Sesame in “Our Family Hot Dog Buns 8 Ct.”

March 21, 2023 By The FDA

Mutual Trading Co., Inc Issues Allergy Alert for Undeclared Soy in Sauces

March 20, 2023 By The FDA

Voluntary Recall of One Lot of Kaytee® Wild Bird Food Birders Blend, 8 Lb Bag, Due to Elevated Levels of Aflatoxin

March 18, 2023 By The FDA

Perrigo Announces Voluntary Recall of Limited Quantity of Gerber® Good Start® SootheProTM Powdered Infant Formula

March 16, 2023 By The FDA

Mockingbird Expands Recall to Include Single Strollers Due to Fall Hazard

March 16, 2023 By The CPSC

J&J Settles Talc Mesothelioma Settlement

January 15, 2020 By Advice Media

Perrigo Announces Voluntary Recall of Limited Quantity of Gerber® Good Start® SootheProTM Powdered Infant Formula

March 16, 2023 By The FDA

Mockingbird Expands Recall to Include Single Strollers Due to Fall Hazard

March 16, 2023 By The CPSC

Updated – Scenic Fruit Company Recalls Frozen Organic Strawberries and Frozen Organic Tropical Blend Because of Possible Health Risk

March 15, 2023 By The FDA

Recall News in Your Inbox

Enter your email address to receive automated recall news updates.

Recent Comments

  • Roger McGowan on ABH NATURE’S PRODUCTS, INC, ABH PHARMA, INC., and STOCKNUTRA.COM, INC. Issues Nationwide Recall of All Lots of Dietary Supplement Products
  • Kathryn Moore on FDA Wants Cancer Warning on Breast Implants
  • BRAD on Huge ATV Recall by Polaris – Sportsman and Scrambler
  • Crystal Anderson on Allergan Voluntarily Recalls BIOCELL® Textured Breast Implants and Tissue Expanders
  • Outsourcing Training on The Modern Marketing of Pain
  • SANDRA Collett on Processed Food Preservative Linked to Autism?
  • Eric Karsh on Health Risks of Roundup Go Well Beyond Cancer

Recent Posts

  • Second Nature Brands Issues Allergy Alert on Undeclared Wheat in Gluten Free Reese’s Pieces Brownie Brittle
  • Kawasaki Motors USA Recalls Engines Sold on Ferris and SCAG Riding Lawn Mowers Due to Burn and Fire Hazards
  • Burnham Commercial Recalls Natural Gas Boilers Due to Burn Hazard (Recall Alert)
  • Textron Specialized Vehicles Recalls Arctic Cat Alterra 600 and
    Tracker 600 All-Terrain Vehicles (ATVs) Due to Crash Hazard
    (Recall Alert)
  • Ascend Laboratories LLC. Issues Voluntary Nationwide Recall of Dabigatran Etexilate Capsules, USP 75 mg and 150 mg, Due to the Detection of N-Nitrosodimethylamine (NDMA) Impurity
  • Perfection Bakeries, d/b/a/ Aunt Millie’s Issues Allergy Alert on Undeclared Sesame in “Our Family Hot Dog Buns 8 Ct.”
  • Mutual Trading Co., Inc Issues Allergy Alert for Undeclared Soy in Sauces
  • Voluntary Recall of One Lot of Kaytee® Wild Bird Food Birders Blend, 8 Lb Bag, Due to Elevated Levels of Aflatoxin
  • Perrigo Announces Voluntary Recall of Limited Quantity of Gerber® Good Start® SootheProTM Powdered Infant Formula
-- See More Recall News

Disclaimer: The information contained in these topics is not intended nor implied to be a substitute for professional medical or legal advice, it is provided for educational purposes only. Always seek the advice of your physician or other qualified healthcare provider about any questions you may have regarding a medical condition. Nothing contained in these topics is intended to be used for medical diagnosis or treatment.


ATTORNEY ADVERTISING. The information provided on this website is not legal advice. No attorney-client relationship is formed by the use of this site. It is not stated or implied that a lawyer is certified as a specialist in any particular field of law. No results are guaranteed, and prior results do not guarantee a similar outcome. This site is informational, only, not dispositive; it is up to you to decide whether a particular lawyer is right for you. Use of this site is subject to your agreement to these.


Copyright © 2023 Altrumedia · Terms of Service · Log in